Lutetium-177 Octreotate
PreclinicalRadiopharmaceutical
Lutetium-177 Octreotate is one of 14 small molecule programs targeting Neuroendocrine Tumors. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Neuroendocrine Tumors
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Keytruda
Merck & Co.Phase 2
Lenvima
EisaiPhase 2
Verzenio
Eli LillyPhase 2
Cabometyx
Bristol-Myers SquibbPhase 1
Surufatinib
HHutchison Medipharma Limited
Phase 2
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Phase 2
Lutathera
AAdvanced Accelerator Applications
Phase 1
VMT-α-NET
PPerspective Therapeutics
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lutetium-177 Octreotate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details